Literature DB >> 26838022

Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Benjamin Arnold1, Sandra A Mitchell2, Lauren Lent1, Tito R Mendoza3, Lauren J Rogak4, Natalie M Barragán4, Gordon Willis5, Mauricio Medina6, Suzanne Lechner7, Frank J Penedo8, Jay K Harness9, Ethan M Basch4,10.   

Abstract

PURPOSE: The U.S. NCI's PRO-CTCAE is a library of self-report items for assessing symptomatic adverse events in cancer clinical trials from the patient perspective. The aim of this study was to translate and linguistically validate a Spanish version.
METHODS: PRO-CTCAE's 124 items were translated from English into Spanish using multiple forward and back translations. Native Spanish speakers undergoing cancer treatment were enrolled at six cancer treatment sites. Participants each completed approximately 50 items and were then interviewed using cognitive probes. The interviews were analyzed at the item level by linguistic themes, and responses were examined for evidence of equivalence to English. Items for which ≥20 % of participants experienced difficulties were reviewed, and phrasing was revised and then retested in subsequent interviews. Items where <20 % of respondents experienced difficulties were also reviewed and were considered for rephrasing and retesting.
RESULTS: One hundred nine participants from diverse Spanish-speaking countries were enrolled (77 in Round 1 and 32 in Round 2). A majority of items were well comprehended in Round 1. Two items presented difficulties in ≥20 % of participants and were revised/retested without further difficulties. Two items presented difficulties in <20 %, and when retested exhibited no further difficulties. Two items presented difficulties in <20 %, but were not revised due to lack of alternatives. Sixteen items presented difficulties in ≤12 % and were not revised because difficulties were minor.
CONCLUSIONS: The Spanish PRO-CTCAE has been developed and refined for use in Spanish-speaking populations, with high levels of comprehension and equivalence to the English PRO-CTCAE. TRIAL REGISTRATION: ClinicalTrials.gov:NCT01436240.

Entities:  

Keywords:  Adverse events; Cancer; PRO-CTCAE; Patient-Reported outcomes; Spanish; Toxicity; Translation

Mesh:

Year:  2016        PMID: 26838022     DOI: 10.1007/s00520-015-3062-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  15 in total

1.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-10       Impact factor: 5.725

2.  Developing instruments for cross-cultural psychiatric research.

Authors:  J A Flaherty; F M Gaviria; D Pathak; T Mitchell; R Wintrob; J A Richman; S Birz
Journal:  J Nerv Ment Dis       Date:  1988-05       Impact factor: 2.254

Review 3.  Outcomes and endpoints in cancer trials: bridging the divide.

Authors:  Michelle K Wilson; Deborah Collyar; Diana T Chingos; Michael Friedlander; Tony W Ho; Katherine Karakasis; Stan Kaye; Mahesh K B Parmar; Matthew R Sydes; Ian F Tannock; Amit M Oza
Journal:  Lancet Oncol       Date:  2014-12-29       Impact factor: 41.316

4.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.

Authors:  A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun
Journal:  Qual Life Res       Date:  1996-06       Impact factor: 4.147

5.  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

Authors:  Diane Wild; Alyson Grove; Mona Martin; Sonya Eremenco; Sandra McElroy; Aneesa Verjee-Lorenz; Pennifer Erikson
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

Review 6.  Electronic toxicity monitoring and patient-reported outcomes.

Authors:  Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner
Journal:  Cancer J       Date:  2011 Jul-Aug       Impact factor: 3.360

7.  Development of three African language translations of the FACT-G.

Authors:  V Mullin; D Cella; C H Chang; S Eremenco; M Mertz; L Lent; C Falkson; G Falkson
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

Review 8.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.

Authors:  Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

Review 10.  Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Authors:  Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

View more
  13 in total

1.  Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.

Authors:  Bryce B Reeve; Molly McFatrich; Laura C Pinheiro; David R Freyer; Ethan M Basch; Justin N Baker; Janice S Withycombe; Lillian Sung; Jennifer W Mack; Mia K Waldron; Catriona Mowbray; Diana Palma; Pamela S Hinds
Journal:  J Pain Symptom Manage       Date:  2017-01-03       Impact factor: 3.612

2.  Perceived Severity of COVID-19 in a Longitudinal Study in Detroit, Michigan.

Authors:  Danting Yang; Abram L Wagner; Sherri Sheinfeld Gorin
Journal:  Ethn Dis       Date:  2022-07-21       Impact factor: 2.006

3.  Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein.

Authors:  Yumi Kosaka; Tomoki Kimura; Tomokazu Kawaoka; Yutaro Ogawa; Kei Amioka; Kensuke Naruto; Yuki Yoshikawa; Chihiro Kikukawa; Yosuke Suehiro; Kenji Yamaoka; Yuwa Ando; Shinsuke Uchikawa; Kei Morio; Takashi Nakahara; Eisuke Murakami; Shoichi Takahashi; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Keigo Chosa; Kazuo Awai; Yasushi Nagata; Kazuaki Chayama; Hiroshi Aikata
Journal:  Liver Cancer       Date:  2021-02-24       Impact factor: 11.740

4.  The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.

Authors:  Takashi Kawaguchi; Kanako Azuma; Motohiko Sano; Soan Kim; Yosuke Kawahara; Yoko Sano; Tomohide Shimodaira; Keiichiro Ishibashi; Tempei Miyaji; Ethan Basch; Takuhiro Yamaguchi
Journal:  J Patient Rep Outcomes       Date:  2018-01-05

5.  Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Tempei Miyaji; Yukiko Iioka; Yujiro Kuroda; Daigo Yamamoto; Satoru Iwase; Yasushi Goto; Masahiro Tsuboi; Hiroki Odagiri; Yu Tsubota; Takashi Kawaguchi; Naoko Sakata; Ethan Basch; Takuhiro Yamaguchi
Journal:  J Patient Rep Outcomes       Date:  2017-12-05

6.  A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.

Authors:  Siu-Fun Wong; Joseph M Unger; James L Wade; Lynne I Wagner; Mario E Lacouture; Keisha C Humphries; Anna Moseley; Kathryn Arnold; Mario R Velasco; Justin D Floyd; Benjamin T Esparaz; Afsaneh Barzi; Heinz-Josef Lenz; Marianna Koczywas; Shaker Dakhil; Gary V Burton; Michael J Fisch; N Lynn Henry; Dawn L Hershman; Carol M Moinpour
Journal:  J Patient Rep Outcomes       Date:  2020-07-08

7.  Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.

Authors:  Juhee Cho; Junghee Yoon; Youngha Kim; Dongryul Oh; Seok Jin Kim; Jinseok Ahn; Gee Young Suh; Seok Jin Nam; Sandra A Mitchell
Journal:  J Glob Oncol       Date:  2019-03

Review 8.  Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.

Authors:  Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-03-07       Impact factor: 46.802

9.  Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.

Authors:  Danilo Galizia; Andrea Milani; Elena Geuna; Rossella Martinello; Celeste Cagnazzo; Manuela Foresto; Virginia Longo; Paola Berchialla; Gianfranca Solinas; Adele Calori; Bruna Grasso; Chiara Volpone; Gisella Bertola; Gisella Parola; Giancarla Tealdi; Piero Luigi Giuliano; Anna Maria Ballari; Massimo Aglietta; Filippo Montemurro
Journal:  Cancer Med       Date:  2018-07-20       Impact factor: 4.452

10.  Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

Authors:  Cheng Kkf; S A Mitchell; N Chan; E Ang; W Tam; R Kanesvaran
Journal:  BMC Cancer       Date:  2020-11-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.